Tumors arising in patients with hereditary cancer syndromes may have distinct drug sensitivity as compared to their sporadic counterparts. Breast and ovarian neoplasms from BRCA1 or BRCA2 mutation carriers are characterized by deficient homologous recombination (HR) of DNA, that makes them particularly sensitive to platinum compounds or inhibitors of poly (ADP-ribose) polymerase (PARP). Outstan...

Breast cancer is the second most common leading cause of death in women. Acquired resistance of breast cancer cells is a challenging field in the research. Cancer becomes due to environmental and hereditary factors like chemicals, viruses, or radiation can cause DNA damage that leads to genetic mutations (Tabar and Dean, 2003). From a long time, many strategies have been developed and followed ...

background: exposure to endogenous hormones such as estrogen is known as a lifetime breast cancer (bc) risk factor. polymorphisms in genes that are involved in the steroidogenic process, such as cytochrome p450c17alpha ( cyp17) , affect individuals’ susceptibility to bc. in iran, the highest incident of bc is among young women. this study aimed to find prevalence of single nucleotide polymorphi...

The history of specific therapy for hereditary tumors dates back to mid 1980s and involves a number of reports demonstrating regression of familial colon polyps upon administration of sulindac. Virtually no clinical studies on other hereditary cancer types were available until the year 2009, when Byrski et al. presented the data on unprecedented sensitivity of BRCA1-associated breast malignanci...

Predisposition to breast and ovarian cancer has been attributed to mutant BRCA1 alleles in 90% of hereditary combined tumors and in 45% of hereditary breast cases, whereas mutations in BRCA2 gene are thought to account for about 35% of inherited breast cancers. On the other hand, the presence of mutations in the sporadic forms of these tumors is an infrequent event. This suggests that tumors ar...

OBJECTIVE To assess the knowledge of nurses involved in the care of oncology patients in a public university hospital, regarding breast cancer and hereditary breast cancer, and to verify the use of such knowledge in their daily practice. METHODS This is a descriptive cross-sectional study. Data were obtained through a structured, self-administered questionnaire. Out of 154 nurses, 137 (88.9%)...

Mutations in BRCA1 confer a high lifetime risk for both breast and ovarian cancer. Many different BRCA1 mutations have been described in families with earlyonset breast and ovarian cancer [1, 2]. The presence of recurrent mutations in BRCA1 suggests the presence of founder effects. BRCA1 “de novo” mutations are very rare. 66 families were studied in Szczecin with strong aggregations of breast/o...